Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Trial Identifier: D0817R00011
Sponsor: AstraZeneca
Start Date: March 2021
Primary Completion Date: September 2025
Study Completion Date: September 2025
Condition: Ovarian Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anhui, China
China Changsha, China
China Chengdu, China
China Chongqing, China
China Dongguan, China
China Foshan, China
China Fujian, China
China Guangzho, China
China Guangzhou, China
China Guizhou, China
China Hangzhou, China
China Hebei, China
China Heilongjiang, China
China Henan, China
China He'nan, China
China Huizhou, China
China Jiangsu, China
China Jiangxi, China
China Jilin, China
China JingHou, China
China Liaoning, China
China Luzhou, China
China Nanjing, China
China Nantong, China
China Ningbo, China
China Shandong, China
China shanghai, China
China Shanghai, China
China Shenyang, China
China Sichuan, China
China Taiyuan, China
China Tianjin, China
China Yichang, China
China Yunan, China
China Zhejiang, China
China Zhengzhou, China